Myelofibrosis Clinical Trials in Seattle, Washington

7 studies are recruiting for myelofibrosis in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

   This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Washington, Seattle, Washington

   Locations

   32 in total

   Run by

   Disc Medicine, Inc

   See if you can join NCT05320198 on ClinicalTrials.gov

2. A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

   The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo. Other aims are to learn how elritercept improves anemia compared to placebo; to learn if elritercept reduces tiredness,…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Washington, Seattle, Washington

   Locations

   195 in total

   Run by

   Takeda

   See if you can join NCT07623161 on ClinicalTrials.gov

3. A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

   This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Washington - Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   90 in total

   Run by

   Sumitomo Pharma America, Inc.

   See if you can join NCT04176198 on ClinicalTrials.gov

4. A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

   The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the …

   Stage

   Phase 2

   Ages

   18 to 66

   Site

   Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   13 in total

   Run by

   Center for International Blood and Marrow Transplant Research

   See if you can join NCT06859424 on ClinicalTrials.gov

5. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Seattle, Washington

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

6. Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

   This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in t…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Centre, Seattle, Washington

   Locations

   215 in total

   Run by

   Kartos Therapeutics, Inc.

   See if you can join NCT06479135 on ClinicalTrials.gov

7. Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

   A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   6 in total

   Run by

   Epigenetix, Inc.

   See if you can join NCT05488548 on ClinicalTrials.gov